Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.49 |
| ▸ | KDM4A | O75164 | 2/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.49 |
| ▸ | PSMD14 | O00487 | 3/20 | 0.46 |
| ▸ | PREP | P48147 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM6B | O15054 | 1/20 | 0.38 |
| ▸ | KDM6A | O15550 | 1/20 | 0.38 |
| ▸ | TET3 | O43151 | 1/20 | 0.38 |
| ▸ | KDM4B | O94953 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7603841 | 0.87 | KDM4E (0.51) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL4519716 | 0.85 | KDM4E (0.68) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| Hydrochloric Acid SCHEMBL15328531 | 0.83 | KDM4E (0.66) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL7370804 | 0.83 | PREP (0.50) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL27908514 | 0.80 | KDM4E (0.44) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL7377364 | 0.80 | PSMD14 (0.68) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL15328824 | 0.80 | SLC40A1 (0.56) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL7368792 | 0.77 | KDM4E (0.57) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL7369890 | 0.76 | NUDT1 (0.52) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL10405412 | 0.74 | PRNP (0.58) | KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108771681-B | Co-crystals of compounds and deuterated derivatives thereof as DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2021-06-15 | — | — | CN | disclosed |
| US-11021465-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-01 | — | — | US | disclosed |
| US-11008305-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3459942-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2020-12-30 | — | — | EP | disclosed |
| CN-106977495-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-10716789-B2 | Co-crystals and pharmaceutical compositions comprising the same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-07-21 | — | — | US | disclosed |
| EP-3424920-B1 | CO-CRYSTALS OF (S)-N-METHYL-8-(1-((2'-METHYL-[4,5'-BIPYRIMIDIN]-6-YL)AMINO)PROPAN-2-YL)QUINOLINE-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20200109130-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-04-09 | — | — | US | disclosed |
| US-20200062732-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-02-27 | — | — | US | disclosed |
| CN-106986863-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2019-12-31 | — | — | CN | disclosed |
| CN-105636958-A | Dna-pk inhibitors | VERTEX PHARMA | 2016-06-01 | — | — | CN | disclosed |
| US-9296701-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-03-29 | — | — | US | disclosed |
| CN-104640852-A | Dna-pk inhibitors | VERTEX PHARMA | 2015-05-20 | — | — | CN | disclosed |
| WO-2015058067-A1 | CO-CRYSTALS OF (S)-N-METHYL-8-(1-((2'-METHYL-[4,5'-BIPYRIMIDIN]-6-YL)AMINO)PROPAN-2-YL)QUINOLINE-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111871-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-23 | — | — | US | disclosed |
| WO-2015058031-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-23 | — | — | WO | disclosed |
| EP-2841428-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20140045869-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-13 | — | — | US | disclosed |
| WO-2013163190-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20130281431-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045869-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | KDM4E 910/4885L3MBTL1 2098/4885KDM4A 1144/4885 |
| US-20200109130-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | KDM4E 910/4885L3MBTL1 2098/4885KDM4A 1144/4885 |
| US-11008305-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | KDM4E 910/4885L3MBTL1 2098/4885KDM4A 1144/4885 |
| US-20150111871-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | KDM4E 910/4885L3MBTL1 2098/4885KDM4A 1144/4885 |
| US-10716789-B2 | Co-crystals and pharmaceutical compositions comprising the same | SUCNR1, SDHA, SDHB | KDM4E 2577/4885L3MBTL1 4839/4885KDM4A 2647/4885 |
| US-20200062732-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | KDM4E 910/4885L3MBTL1 2098/4885KDM4A 1144/4885 |
| US-20130281431-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | KDM4E 910/4885L3MBTL1 2098/4885KDM4A 1144/4885 |
| US-11021465-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | KDM4E 910/4885L3MBTL1 2098/4885KDM4A 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.